DeepCure closed a $24.6M Series A-1 funding round led by IAG Capital Partners to further develop its cutting-edge technology for immunology and inflammation pipeline.

Apr 11, 2024•over 1 year ago

Amount Raised

$24.6 Million

Round Type

series a

BostonArtificial IntelligenceHealth CareSoftware

Investors

Iag Capital Partners

Description

DeepCure announced the closing of a $24.6 million Series A-1 financing led by IAG Capital Partners with participation from the company’s current investors. The proceeds will be used to further develop DeepCure’s cutting-edge technology, and to advance its immunology and inflammation pipeline towards clinical trials.

Company Information

Company

DeepCure

Location

Boston, Massachusetts, United States

About

DeepCure was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists and biologists. Our founding team includes some of the industry’s preeminent drug-discovery scientists and technologists. Our vision is to use AI-driven discovery to create better molecules and faster cures for every disease-relevant protein target.

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

DeepCure closed a $24.6M Series A-1 funding round led by IAG Capital Partners to further develop its cutting-edge technology for immunology and inflammation pipeline.

Investors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Related People

Company Information